Welcome to our dedicated page for Zimmer Biomet Holdings news (Ticker: ZBH), a resource for investors and traders seeking the latest updates and insights on Zimmer Biomet Holdings stock.
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) is a preeminent global leader in musculoskeletal healthcare. Headquartered in Warsaw, Indiana, Zimmer Biomet has been at the forefront of advancing bone and joint health for nearly 90 years. The company designs, manufactures, and markets a comprehensive range of orthopedic implants and surgical equipment, addressing joint reconstruction, bone repair, sports medicine, spine, and dental reconstruction. Its innovative product portfolio includes the ROSA® Robotics systems for knee, hip, and shoulder replacements, and the TMINI Miniature Robotic System for total knee arthroplasty.
Zimmer Biomet's latest endeavors include the establishment of a dedicated Health Equity division in 2023, which aims to integrate health equity into the company's core strategies and operations. This division has already made significant strides by assembling a strategic advisory board and developing the Community Centered Care (C3) framework to increase patient access to quality care in underserved communities.
In addition, Zimmer Biomet has recently partnered with top pickleball organizations in the U.S., underscoring its commitment to joint health and well-being for the growing community of pickleball players. The company also announced a strategic alliance with CBRE Group, Inc. to expand orthopedic ambulatory surgery centers across the country, and a collaboration with RevelAi Health to commercialize AI-powered engagement solutions aimed at advancing value-based orthopedic care and health equity.
Financially, Zimmer Biomet has demonstrated robust performance, with first-quarter 2024 net sales amounting to $1.889 billion, a 3.2% year-over-year increase. The company continues to focus on innovation, operational excellence, and strategic partnerships to drive growth and enhance shareholder value. For more information, visit www.zimmerbiomet.com or follow them on LinkedIn and Twitter.
Zimmer Biomet Holdings has appointed Ivan Tornos as Chief Operating Officer, effective March 19, 2021. Tornos, who joined the company in November 2018, will oversee all global businesses and lead operations, clinical education, and R&D. He continues to lead the Americas and now adds the EMEA region to his responsibilities. The company also announced Didier Deltort's departure as President of EMEA, effective immediately, with a search underway for his replacement. Tornos brings extensive experience from Becton, Dickinson, and C.R. Bard.
Zimmer Biomet Holdings has announced a quarterly cash dividend of $0.24 per share for the first quarter of 2021. The dividend is payable on April 30, 2021, to stockholders of record by March 29, 2021. The company continues to lead in musculoskeletal healthcare, providing a range of products for orthopedic reconstruction, sports medicine, and more. With operations in over 25 countries, Zimmer Biomet aims to enhance patient care through innovative solutions.
Zimmer Biomet Holdings announced significant changes to its Board of Directors. Sreelakshmi Kolli, Chief Digital Officer at Align Technology, joins the board immediately. Larry C. Glasscock, the Non-Executive Chairman, will retire in May 2021 as per governance guidelines. Following his retirement, Bryan C. Hanson, the current President and CEO, will assume the role of Chairman. Christopher B. Begley will become the Lead Independent Director. Additionally, Gail K. Boudreaux has opted not to seek reelection at the upcoming annual meeting. These changes reflect Zimmer Biomet's ongoing strategic initiatives.
Zimmer Biomet Holdings (NYSE: ZBH) announced that President and CEO Bryan Hanson and CFO Suky Upadhyay will present at the Cowen 41st Annual Health Care Conference on March 4, 2021, at 11:10 a.m. ET. The presentation will be accessible via a live webcast on Zimmer Biomet's Investor Relations website and will be archived for replay.
Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet is a leader in musculoskeletal healthcare, providing innovative orthopedic and surgical products worldwide.
Zimmer Biomet Holdings, Inc. has appointed Vafa Jamali as the CEO of NewCo, a spin-off company which will focus on the Spine and Dental sectors, expected to launch in mid-2022. Jamali brings over 25 years of medical device experience, previously holding leadership roles at Rockley Photonics and Medtronic, where he led a $3 billion revenue division. His expertise is anticipated to drive growth and investment strategies for NewCo. Bryan Hanson, the current CEO of Zimmer Biomet, expressed confidence in Jamali’s ability to lead the new venture successfully.
Zimmer Biomet (ZBH) announced that President and CEO Bryan Hanson, along with Executive Vice President and CFO Suky Upadhyay, will present at Citi's 2021 Healthcare Services Conference on February 24, 2021, at 10:45 a.m. ET. A live webcast can be accessed via their Investor Relations website, which will also archive the presentation for later viewing. Zimmer Biomet, headquartered in Warsaw, Indiana, is a key player in musculoskeletal healthcare, offering a wide range of medical products and solutions.
Zimmer Biomet (NYSE: ZBH) plans to spin off its Spine and Dental businesses into a new independent company, NewCo, aiming to optimize growth and stakeholder value. This strategic move, part of Zimmer Biomet's transformation, focuses resources on higher-growth markets, including orthopedics and dental sectors. The spin-off, expected mid-2022, is designed to create stronger growth profiles for both companies while achieving a more targeted investment opportunity. The 2019 and 2020 pro forma revenue for Zimmer Biomet was $6.96 billion and $6.128 billion, respectively.
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) reported its Q4 2020 results, revealing net sales of $2.085 billion, down 1.9%, with full-year sales at $7.025 billion, a 12% decrease. Q4 net earnings reached $333.7 million, equating to diluted EPS of $1.59, a 3.2% increase year-over-year. Adjusted diluted EPS fell 8.3% to $2.11. The company announced plans to spin off its Spine and Dental divisions to enhance focus and growth. Despite strong operational performance, the ongoing impact of COVID-19 on elective procedures continues to hinder recovery.
Zimmer Biomet Holdings has appointed Ellison M. Humphrey as the Chief Transformation Officer, reporting directly to Bryan C. Hanson, President and CEO. Humphrey joins from Medtronic, where she held leadership roles including Vice President of Enterprise Excellence. In her new role, she will connect key initiatives to drive an integrated transformation strategy across the organization. Her extensive experience, including a background at McKinsey & Company and degrees from Harvard and the University of Virginia, is expected to advance Zimmer Biomet’s goals within the evolving healthcare landscape.
Zimmer Biomet Holdings (ZBH) will host a fourth quarter earnings conference call on February 5, 2021, at 8:30 a.m. ET, following a news release of financial results at 6:30 a.m. ET the same day. The conference call will be accessible via their Investor Relations website and will be archived for replay. U.S. and Canadian participants can join by calling (888) 312-9837 using conference ID 7278985. The digital recording will be available until April 6, 2021.
FAQ
What is the current stock price of Zimmer Biomet Holdings (ZBH)?
What is the market cap of Zimmer Biomet Holdings (ZBH)?
What does Zimmer Biomet do?
Where is Zimmer Biomet headquartered?
What are Zimmer Biomet's latest innovations?
What is Zimmer Biomet's focus on health equity?
How did Zimmer Biomet perform financially in the first quarter of 2024?
What are Zimmer Biomet's partnerships?
What is the ROSA® Robotics system?
What is the Community Centered Care (C3) framework?
What is Zimmer Biomet's role in pickleball?
How does Zimmer Biomet contribute to innovation in healthcare?
